NM49 / Numab - LARVOL DELTA

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer (GlobeNewswire) - "Numab Therapeutics AG...announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform....Under the terms of the agreement, Ono has obtained an option to in-license NM49 from Numab for global development and commercialization, with Numab retaining an option to co-develop and commercialize in the United States."

Licensing / partnership • Oncology • Solid Tumor